 |
The Journal of Clinical Psychopharmacology PodcastAuthor: The Journal of Clinical Psychopharmacology
A podcast detailing current topics in the Journal of Clinical Psychopharmacology. Language: en Genres: Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
The Use of VMAT2 Inhibitors for Tardive Dyskinesia
Wednesday, 4 March, 2026
In this podcast, Orges Alabaku discusses his article, "The Use of VMAT2 Inhibitors for Tardive Dyskinesia," which is published in the March-April 2026 issue of the Journal of Clinical Psychopharmacology. As Dr. Albaku notes, tardive dyskinesia (TD) is a potentially severe and often persistent movement disorder associated with prolonged exposure to dopamine receptor-blocking agents, particularly antipsychotic medications. The only FDA-approved medications for TD are vesicular monoamine transporter 2 inhibitors (VMAT2-Is), valbenazine and deutetrabenazine, while another VMAT2-I medication, tetrabenazine, is used off-label. However, data about VMAT2-I use remain limited. In their study, Dr. Alabaku and colleagues Mark Olfson, T. Scott Stroup, and Tobias Gerhard characterized trends in TD diagnosis and VMAT2-I use among adults with mental health diagnoses receiving antipsychotics by analyzing 2017-2022 MarketScan data. They report that TD remains underdiagnosed, with treatment rates low, highlighting the need for improved TD recognition and VMAT2-I access. doi: 10.1097/JCP.0000000000002155
